The transformative positive impacts of the AMP-inducer technology could be considerable for our society, economy, and environment in several ways. (i) To improve public health, by helping to control the spread of AMR, which could reduce the number of infection-related diseases. More than 1,2 million people worldwide die each year from infections caused by AMR. Products arising from MaxImmun could lower the burden of disease related to these cases. (ii) To reduce healthcare costs associated with AMR infections. According to the WHO, the direct medical costs of treating AMR infections can be up to 20 times higher than the costs of treating infections with antibiotics that are effective. In Europe, AMR costs €1,5 billion per year in healthcare costs and productivity losses. In the long term, the AMP-inducer technology could help to lower these economic losses and to increase productivity and economic growth by helping to reduce work absences related to these infections. (iii) To create a new market and associated jobs for innovative antimicrobials such as AMP inducers, by taking advantage of the “broken” antibiotic market. Our technology will emerge in the current context of the market reform needed to encourage investment and expand the razor-thin pipeline of new antimicrobials in development. With big pharma vacating the space, there are few new antimicrobials currently in the clinical pipeline, most of them being developed by SMEs. (iv) Regarding environmental protection, our technology could help to reduce the amount of antibiotics used, which could reduce pollution, negative impacts on the environment, and help to maintain healthy ecosystems. Classical resistance formation by low levels of residual antibiotics is prevented by the MaxImmun approach. Therefore, the AMP-inducer technology may provide a long-term sustainable solution against AMR, and may also protect from AMR spread in the environment or among animals. (v) To improve quality of life of patients, by stimulating their own defenses for a better health. Beyond the AMR breaking indication, drugs arising from MaxImmun may also be a model that induces a paradigm shift for other diseases: rather than directly targeting a pathology with exogeneous chemicals, the drug elicits a natural endogenous response of the body. This concept of activating the body’s own healing power might be applicable to other diseases. Ultimately, uptake and success of the AMP-inducer technology will depend on how it will be implemented and managed by policy makers, scientists, medical staff and patients.
